What you need to know
Be prepared to advocate
Know the right resources
Educate healthcare providers
Stay informed and connected
10 things you should remember about neurofibromatosis type 1 (NF1)
-
1.
NF1 is a condition that affects approximately 1 in 3000 individuals.1
-
2.
Early diagnosis allows patients and carers access to help, resources and support.
-
3.
NF1 causes tumours to grow on nerves and affects everyone in a different way. NF1 can lead to learning difficulties – sometimes needing extra support at school – and problems with bones, eyes and the nervous system.1, 2
-
4.
Having multiple birth marks may be a sign of NF1; 95% of those with NF1 will have 6 or more brown-coloured marks (Cafe au Lait marks).
-
5.
NF1 can affect anyone: Half of those with NF1 will have inherited the condition from a parent with NF11, 2 The other half will be the first in the family with no previous family history.1
-
6.
Symptoms and severity of NF1 can change over time. making life-long monitoring important.
-
7.
Mosaic (also called localised or segmental) NF1 affects specific areas of the body, leaving the rest of the skin unaffected. Mosaic NF1 is far less common than ‘generalised’ NF1, which affects the whole body.
-
8.
While everyone should take precautions to reduce the risk of cancer, individuals with NF1 need to be especially careful. They should take actions such as minimising exposure to radiation and use high-protection sunscreen, to reduce their risk.
-
9.
Patients, parents and caregivers are encouraged to reach out to networks and relevant organisations to access help, support and resources.
-
10.
With proper support those living with NF1 can lead fulfilling lives.
Reference
-
1Hernandez-Martin A and Duat-Rodriguez A. An update on neurofibromatosis type 1: not just cafe-au-lait spots, freckling, and neurofibromas. An update part L dermatological clinical criteria diagnostic of the disease. Actas Dermosifiliogr 2016;107:454-64.
-
2Choi J, An S and Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Arch Craniofac Surg 2022;23:6-16.